NCT00001999已完成不适用
A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
To evaluate whether immune globulin and ganciclovir (DHPG) results in faster initial response as compared to DHPG alone. To evaluate whether immune globulin and DHPG gives longer duration of remission than DHPG alone (i.e. 16 weeks). To evaluate the toxicities of the combination of DHPG and immune globulin as compared to those of DHPG alone. To evaluate if there is a difference between the two groups in regard to survival, immune functions, and CMV viremia and viruria.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have the following:
- •First episode of sight-threatening CMV retinitis.
- •At least one pending culture for CMV from the blood or urine prior to entry.
- •Life expectancy > 6 months.
- •Karnofsky performance = or >
- •Ability to understand the nature of the study, to comply with study requirements, and to sign informed consent.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions are excluded:
- •Known selective IGA deficiency or antibodies against IgA.
- •History of previous episodes of sight-threatening CMV retinitis.
- •Patients with the following are excluded:
- •Previous episode of sight-threatening CMV retinitis.
- •Concomitant treatment with other investigational agents except ddI or ddC.
- •Life expectancy < 6 months.
- •Continued alcohol or drug abuse.
- •Known selective IgA deficiency and known to have antibodies against IgA.
- •Karnofsky performance <
- •Other investigational agents except ddI or ddC.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade GliomasGlioma, MalignantNCT03576612Candel Therapeutics, Inc.41
Unknown
1 期
Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus InfectionRotavirus InfectionNCT04626856Chinese Academy of Medical Sciences32
已完成
1 期
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney TransplantationEnd Stage Renal DiseaseNCT01178216Stanley Jordan, MD41
已完成
不适用
A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast CancerBreast CancerNCT00477139Stanford University4
已完成
3 期
Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency PatientsImmunologic Deficiency SyndromeAgammaglobulinemiaWiskott-Aldrich SyndromeSevere Combined ImmunodeficiencyCommon Variable ImmunodeficiencyNCT00220766Grifols Therapeutics LLC100